Dupixent 300 MG/2 ML pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FM1LB
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $35,824
Award facts
- Contract value 100% obligated
- $35,824.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors, with a contract ceiling value of approximately $35.8K and an ultimate completion date of September 12, 2025. The award was competitively procured with no set-aside designation and employs firm fixed-price pricing. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly within the Defense Health Agency and military healthcare systems. This delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 and extends through December 2026.
The SPE2DX contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and diagnostic test kits across multiple therapeutic domains. Dupixent is a biologic immunosuppressant medication used to treat moderate-to-severe eczema, asthma, and other inflammatory conditions. The current delivery order represents a single transaction within AmerisourceBergen's broader framework of federal medical supply contracts, demonstrating the company's continued role as a primary pharmaceutical vendor for Department of Defense medical supply chain requirements.
Quick answers
Who was awarded contract SPE2DB25FM1LB?
SPE2DB25FM1LB was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 11, 2025.
How much is contract SPE2DB25FM1LB worth?
The government has obligated $35,824 on SPE2DB25FM1LB.
Is contract SPE2DB25FM1LB an order under another contract?
Yes. SPE2DB25FM1LB is a delivery order under SPE2DB22D2009, an indefinite delivery contract.
Was contract SPE2DB25FM1LB competed?
The extent of competition for SPE2DB25FM1LB was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award